Meeting ID: 981 2806 6231 Passcode: 848194 One tap mobile +16468769923,,98128066231# US (New York) +16465189805,,98128066231# US (New York)
Dial by your location +1 646 876 9923 US (New York) +1 646 518 9805 US (New York) Meeting ID: 981 2806 6231 Find your local number: https://meetmsk.zoom.us/u/acLK4eNRzf
Day 3 Course Schedule-March 22, 2023
*Course times (Eastern Standard Time)
Time (EST)
Topic:
Presenter(s):
11:00-12:00pm
Adoptive T cell approaches
Dr. Michel Sadelain
12:00-12:55pm
RCR Small Group Sessions
Jedd, Maggie, Ushma
12:55-1:25pm
30 min lunch break
BREAK
1:25-2:20pm
Clinical Trial Design and Statistical Consideration in the Development of IO
Dr. Katherine Panageas
2:20-3:35pm
Workshop on Flow Cytometry
Dr. Rui Gardner
3:35-3:45pm
10 min break
BREAK
3:45-4:45pm
Workshop on Immune Monitoring
Dr. Phil Wong
4:45-5:20pm
Radiographic Endpoints for Immunotherapy Clinical Trial Design
Dr. Michael Postow
5:20-5:30pm
Take Homes
Jedd, Maggie, Ushma
March 2023- Immuno-Oncology for the Translational Researcher Short Course (ITRSC)
About this course
The Memorial Sloan Kettering Cancer Center (MSKCC) Immuno-oncology for the Translational Researcher Short Course (ITRSC) is a cancer education and research experience that will enable eligible junior NCI-funded faculty to learn about tumor immunology, current immunotherapy-based clinical practice and cutting-edge translational research under the mentorship of expert MSKCC faculty. Program participants will attend an intensive 3-day virtual course, led by those centrally involved in basic and clinical immuno-oncology research. ITRSC participants will also have an opportunity to seek additional mentorship and guidance from world experts on immuno-oncology.
The objective of the ITRSC is to engage participants in an in-depth and participatory educational experience covering the topics relevant to clinical immunotherapy research and practice today: checkpoint blockade, novel immunomodulatory antibodies, cellular therapy, immune-monitoring, clinical trial design and development and points of integration with traditional cancer therapy.